Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus KEFUROX IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME IN PLASTIC CONTAINER versus KEFUROX IN PLASTIC CONTAINER.
CEFEPIME IN PLASTIC CONTAINER vs KEFUROX IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3. It demonstrates broad-spectrum activity against gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
1-2 g intravenously every 8-12 hours for moderate to severe infections; up to 2 g every 8 hours for severe infections or febrile neutropenia.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
None Documented
None Documented
2.0–2.3 hours in adults with normal renal function; prolonged to 13–26 hours in end-stage renal disease.
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Renal: approximately 85% of the dose excreted unchanged in urine; biliary/fecal: less than 1%.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic